Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on SAB Biotherapeutics (NASDAQ:SABS) with a $25 price target.
August 12, 2024 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Keay Nakae maintains a Buy rating on SAB Biotherapeutics with a $25 price target.
The reaffirmation of a Buy rating and a $25 price target by Chardan Capital is a positive signal for investors, likely boosting short-term confidence and demand for SABS shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100